LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "emicizumab" as a keyword



EMICIZUMAB DOSING IN CHILDREN AND ADULTS WITH HEMOPHILIA A: SIMULATING A USER-FRIENDLY AND COST-EFFICIENT REGIMEN.

Sign Up to like & get
recommendations! Published in 2021 at "Thrombosis and haemostasis"

DOI: 10.1055/a-1499-0030

Abstract: BACKGROUND When emicizumab is dosed according to label, clinicians are obligated to discard or overdose medication due to discrepancies between calculated dose and vial content. The aim of this study was to compose a cost-efficient… read more here.

Keywords: emicizumab dosing; cost; alternative dosing; cost efficient ... See more keywords

Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.

Sign Up to like & get
recommendations! Published in 2020 at "Thrombosis and haemostasis"

DOI: 10.1055/s-0040-1710315

Abstract: BACKGROUND  Emicizumab prophylaxis is a promising treatment that reduces bleeding events in severely affected patients with hemophilia A (PwHA). It is anticipated that emicizumab could be similarly effective in mild/moderate PwHA (PwMHA) although this effect… read more here.

Keywords: min1; improves vivo; emicizumab improves; pwmha ... See more keywords

Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Medical Economics"

DOI: 10.1080/13696998.2022.2115777

Abstract: Abstract Background and objective A cost-minimization model was developed to compare recombinant factor VIII Fc (rFVIIIFc) and emicizumab as prophylaxis for hemophilia A without inhibitors. Methods The model was based on 100 patients from the… read more here.

Keywords: recombinant factor; without inhibitors; cost; emicizumab ... See more keywords

Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V

Sign Up to like & get
recommendations! Published in 2018 at "British Journal of Haematology"

DOI: 10.1111/bjh.15525

Abstract: Activated protein C (APC) inactivates activated factor V (FVa) and moderates FVIIIa by restricting FV cofactor function. Emicizumab is a humanized anti‐FIXa/FX bispecific monoclonal antibody that mimicks FVIIIa cofactor function. In recent clinical trials in… read more here.

Keywords: protein; activated factor; activated protein; inactivation ... See more keywords

Laboratory issues in gene therapy and emicizumab

Sign Up to like & get
recommendations! Published in 2020 at "Haemophilia"

DOI: 10.1111/hae.13976

Abstract: The treatment options for the haemostatic disorders, haemophilia A and haemophilia B, have progressed rapidly over the last decade. The introduction of extended half‐life recombinant factor VIII (FVIII) and factor IX (FIX) concentrates to replace… read more here.

Keywords: emicizumab; factor; laboratory issues; gene therapy ... See more keywords

Anti‐idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab

Sign Up to like & get
recommendations! Published in 2022 at "Haemophilia"

DOI: 10.1111/hae.14662

Abstract: Emicizumab markedly shortens the activated partial thromboplastin time (aPTT), resulting in inaccurate measurements of procoagulant and anticoagulant factor activities. We have recently reported that mixtures of two different anti‐idiotype monoclonal antibodies against emicizumab (anti‐emicizumab‐mAbs) allow… read more here.

Keywords: procoagulant anticoagulant; anti idiotype; emicizumab; antibodies emicizumab ... See more keywords

Assessment of the clinical perception, quality of life and satisfaction of patients with severe congenital haemophilia A without inhibitor after 1 year of emicizumab therapy

Sign Up to like & get
recommendations! Published in 2023 at "Haemophilia"

DOI: 10.1111/hae.14755

Abstract: Since the approval by the EMA of emicizumab for the care of severe haemophilia A without inhibitor, most of the patients of our haemophilia treatment centre started this new treatment. Thanks to the setting of… read more here.

Keywords: without inhibitor; clinical perception; haemophilia without; emicizumab ... See more keywords

Estimating the Factor VIII‐Equivalent Activity of Emicizumab Using Global Assays of Haemostasis

Sign Up to like & get
recommendations! Published in 2025 at "Haemophilia"

DOI: 10.1111/hae.70085

Abstract: Emicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII‐equivalent activity (FVIIIeq) of emicizumab remains unknown. read more here.

Keywords: estimating factor; factor viii; emicizumab; equivalent activity ... See more keywords
Photo by nci from unsplash

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

Sign Up to like & get
recommendations! Published in 2021 at "Journal of Thrombosis and Haemostasis"

DOI: 10.1111/jth.15187

Abstract: As the first non‐factor replacement therapy for persons with congenital hemophilia A (PwcHA), emicizumab's safety profile is of particular interest to the community. read more here.

Keywords: mortality framework; application hemophilia; hemophilia mortality; safety ... See more keywords

Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial

Sign Up to like & get
recommendations! Published in 2022 at "BMJ Open"

DOI: 10.1136/bmjopen-2021-056922

Abstract: Introduction Subcutaneous emicizumab prophylaxis substantially reduces bleeding episodes in patients with haemophilia A (PwHA) and factor VIII inhibitor. However, thrombotic events occurred in some PwHA with inhibitor who had received high cumulative doses of activated… read more here.

Keywords: unebi study; coagulation; bypassing agents; inhibitor ... See more keywords

NuPOWER (Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis): protocol for an open-label, single-arm, multicentre study

Sign Up to like & get
recommendations! Published in 2025 at "BMJ Open"

DOI: 10.1136/bmjopen-2025-102657

Abstract: Introduction Despite the known haemostatic action of emicizumab (Hemlibra) in haemophilia A patients, its role in the prevention and control of bleeding in high-demand haemostatic situations, such as major surgery, remains to be determined. Patients… read more here.

Keywords: prophylaxis; efficacy; simoctocog alfa; study ... See more keywords